Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ MEDTECH — Restructuring (Note 12)

Other segment segments

Orthopaedics Restructuring Plan
$307M—
Medtech Ortho Franchise
$152M+15.2%

Similar metrics at other companies

AngioDynamics logo
ANGOMed Tech — Cost of sales (exclusive of intangible amortization)
$13.99M+19.0%
Novanta logo
NOVTMedical Solutions — Restructuring Costs
$506K+517%
Extreme Networks logo
EXTRRestructuring And Related Charges
$0+100%
ITT logo
ITTMotion Technologies — Total restructuring costs
$500K+150%
INT
INTTProcess Technologies — Restructuring costs
$22K-93.0%
Gentherm logo
THRMMedical Segments — Restructuring Charges
$36K—

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RestructuringCharges.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's medtech — restructuring (note 12).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's MEDTECH — restructuring (note 12)?
Johnson & Johnson (JNJ) reported MEDTECH — restructuring (note 12) of $100M in Q1 2026.
How has Johnson & Johnson's MEDTECH — restructuring (note 12) changed year-over-year?
Johnson & Johnson's MEDTECH — restructuring (note 12) increased by 81.8% year-over-year, from $55M to $100M.
What is the long-term trend for Johnson & Johnson's MEDTECH — restructuring (note 12)?
Over 3 years (2021 to 2025), Johnson & Johnson's MEDTECH — restructuring (note 12) has grown at a 11.5% compound annual growth rate (CAGR), from $400M to $555M.
What does MEDTECH — restructuring (note 12) mean?
This metric tracks the costs associated with reorganizing the medical technology segment's operations, such as workforce reductions, facility closures, or process improvements. These expenses are incurred to improve long-term operational efficiency and cost structure. Investors monitor these to assess the company's commitment to margin expansion and operational agility.